Human · Sponsor report
What do the newer phase 3 results add?
28.3% reported weight reduction80 weeks; 12 mg; efficacy analysis; sponsor topline report. Treatment-regimen estimate: 25.0%.
Sponsor-reported findings
Lilly reported 28.3% average weight reduction at 80 weeks for 12 mg using the efficacy analysis; the treatment-regimen analysis reported 25.0%.
What might this mean? · interpretation
The report extends the weight-loss signal into a larger phase 3 program.
What might this mean, and what would change the interpretation?
Sponsor-reported topline results. Different analysis assumptions produce different estimates; this was not a direct tirzepatide comparison.
What would clarify this: Full peer-reviewed reporting and the TRIUMPH-5 direct comparison.